Previous 10 | Next 10 |
2023-10-08 17:52:39 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript As F...
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRAS G12C Inhibitor Approved by the U.S. FDA for the Treatment of P...
2023-10-08 15:18:00 ET As the FDA continues to mull the fate of Amgen's lung cancer drug Lumakras, Sanofi is reportedly moving in on Mirati ( NASDAQ: MRTX ), which has developed a rival product called Krazati. Analysts appear to be divided on whether the FDA will end up denying ...
2023-10-05 15:13:58 ET More on Amgen Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript) Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript) Amgen: Not An Investment Mistake, But It Was Better Before Amgen ...
2023-10-05 14:35:52 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...
2023-10-05 12:48:51 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Jone...
2023-10-03 16:35:34 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...
2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...
2023-09-28 16:18:43 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...
Mirati To Present Updated Clinical Data at ESMO Congress 2023 PR Newswire Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in co...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...